Etomidate acid
CAS: 56649-48-0
Ref. 3D-GCA64948
| 2mg | Discontinued | ||
| 5mg | Discontinued | ||
| 10mg | Discontinued | ||
| 25mg | Discontinued | ||
| 50mg | Discontinued | ||
| 100mg | Discontinued | ||
| 250mg | Discontinued |
Product Information
- (R)-(+)-1-(1-Phenylethyl)-1H-imidazole-5-carboxylic acid
- (R)-(+)-1-(1-Phenylethyl)-1H-imidazole-5-carboxylicacid
- 1-((1R)-1-Phenylethyl)-1H-imidazole-5-carboxylic acid
- 1H-Imidazole-5-carboxylic acid 1-[(1R)-1-phenylethyl]-
- 1H-Imidazole-5-carboxylic acid, 1-(1-phenylethyl)-, (R)-
- 1H-Imidazole-5-carboxylicacid, 1-(1-phenylethyl)-, (R)-
- R 28141
Etomidate is a potent, short-acting sedative used in the induction of general anesthesia. It binds to the GABA receptor at multiple sites and increases the duration of chloride channel opening. Etomidate also inhibits spontaneous activity, such as locomotion, in animals. It has been shown that etomidate is metabolized by hydrolysis to form an acid carboxylate and an aliphatic or aromatic hydrocarbon. This drug also has an inhibitory effect on the pharmacokinetics of other drugs, such as midazolam, when administered concomitantly with it. The effective dose for humans is 0.1 mg/kg body weight. Etomidate is not recommended for use in pregnant women or children younger than 18 years old due to its potential side effects on the central nervous system and adrenal glands.
